Navigation Links
UT MD Anderson, Texas A&M team up to treat canine lymphoma
Date:2/7/2012

A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports. The study resulted from a collaboration between The University of Texas MD Anderson Children's Cancer Hospital in Houston and Texas A&M University College of Veterinary Medicine in College Station.

Using a T-cell therapy developed at MD Anderson Children's Cancer Hospital, veterinarians from Texas A&M saw a nearly four-fold improvement in tumor-free survival compared to dogs who received only chemotherapy. The median tumor-free survival for the Texas-based dogs increased by close to nine months, which is roughly equivalent to seven years in a human life span.

NHL is one of the most common cancers in dogs, according to Texas A&M veterinarians. Although standard chemotherapy can achieve remission, it is rarely a curative treatment, with the two-year survival rate remaining less than 20 percent. When investigators from MD Anderson and Texas A&M met, they explored the feasibility of administering T cells to improve survival.

"We followed the same rigid standards that we practice for human clinical trials at MD Anderson to ensure the safety of each dog," said Laurence Cooper, M.D., Ph.D., professor and section chief of cell therapy at the children's hospital and senior investigator on the study. "While these pets are benefiting from the T-cell infusions, this collaboration with Texas A&M is a driving force for undertaking similar clinical trials in humans."

To accomplish the T-cell therapy, researchers took a sample of peripheral blood from each dog entering the study. Then the T cells were separated and expanded in Cooper's laboratory over several weeks. As the T cells grew at MD Anderson, the canines received a chemotherapy regimen at Texas A&M similar to what humans with NHL receive, a combination of cyclophosphamide, vincristine, doxorubicin and prednisone. The T cells were then given back intravenously after the chemotherapy to improve the anti-tumor effects.

"The therapy was well tolerated in all dogs who received the infusions. We saw fewer side effects than with traditional chemotherapy, and the pet owners were please with how their dogs tolerated the protocol," said Heather Wilson-Robles, DVM, DACVIM(Oncology), assistant professor at Texas A&M. "The owners were also very pleased to be supporting research that may further enhance cancer therapy in humans and pets with cancer."

"Treating dogs with cancer provides us with a great comparative oncology model for humans," said Colleen O'Connor, Ph.D., post-doctoral fellow at MD Anderson and one of the primary investigators on the study. "We learned important details about the interaction between chemotherapy and tumor cells that can be harnessed to improve the body's immune response. This is something we hadn't appreciated thus far from our clinical research in humans."

From the trial, investigators found that:

  • Chemotherapy, while damaging the canine tumor, also makes the tumor cells susceptible to recognition by the infused T cells
  • Infusing back the patient's T cells after chemotherapy can work to improve the survival of canines with NHL, since these T cells were held outside the body preventing damage from the chemotherapy
  • Biomarkers were identified that can potentially play a role in determining prognosis

Overall the study further affirmed the ability to use the body's own immune cells, such as T cells, to fight cancer. As a result, MD Anderson and Texas A&M collaborators are creating a program focusing on harvesting and expanding T cells at a large scale for broad clinical use.

Investigators at both institutions are working to open a new trial that will infuse genetically modified T cells that are tumor specific and potentially even more effective against the canine cancer cells.


'/>"/>

Contact: Sara Farris
sfarris@mdanderson.org
713-792-9133
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Research finds Medicare and private insurance spending similar throughout Texas
2. Scott & White Healthcare is 1 of 3 in Texas to receive workforce development grants
3. TB Outbreaks in Texas Schools Show Disease Still a Threat
4. 2 scientists at the University of Texas at Austin receive early career awards from White House
5. Internationally recognized BME professor to join University of Texas as visiting scholar
6. Drug recognition program available for Texas employers
7. Bad cholesterol not as bad as people think, shows Texas A&M study
8. Largest physics meeting of the year: March 20-25, 2011, Dallas, Texas
9. Wild Hogs in Texas Pose Infection Risk to Humans
10. Texas Center for Cancer Nanomedicine targets 2 tough cancers
11. Health IT program at the University of Texas at Austin receives $2.7 million in federal funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
Breaking Medicine Technology: